All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 2, 2021
Home » Blogs » BioWorld Perspectives » Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?

Jan. 19, 2012
By Trista Morrison
No Comments

When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants. “What’s the catch?” everyone keeps asking. “What does J&J get out of the deal?”

I’m guessing J&J execs asked that same question when Diego Miralles, J&J West Coast site head, pitched them on his idea for a no-strings-attached incubator business model. And I’m guessing his answer was something along the lines of “well we’ve got all this expensive equipment and extra lab space anyway, so why not make a little rent money and support innovation and, while we’re at it, get ourselves in the loop with local start-ups who might one day reward our kindness with preference in licensing deals.”

Something like that, anyway.

J&J is a public company with a fiduciary duty to its shareholders, so I’m sure it’s getting some benefit out of this incubator. But the biggest benefit, according to Miralles, is supporting innovation. "A healthy biotech sector is critical to our future. We believe the tide will rise for all ships, and we will all benefit,” he told BioWorld Today back in October when we first wrote about the incubator, which launched last week.

For years VCs and start-ups have been warning that if the industry doesn’t find a way to support innovation, there won’t be any more candidates for big pharma to in-license. It seems J&J is heeding that warning.

I wonder if other pharmas will follow suit. Maybe it will be like when Warren Buffett said he’d match any voluntary contributions Republican congressmen make to pay down the deficit – the deficit is a problem for all of us, so he’s challenging the politicians to step up to the plate and help fix it. Maybe other big pharmas will see that J&J is trying to address the early stage funding gap and they’ll rise to the challenge as well. One can hope . . .

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing